REG-ABCAM Plc Director/PDMR Shareholding
http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20091109:RnsI2317C
.
RNS Number : 2317C
ABCAM Plc
09 November 2009
For immediate release 9November 2009
ABCAM PLC
("Abcam" or "the Company")
Director/PDMR Dealings: Share Incentive Plan
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that
markets antibodies via its own online catalogue, has today been notified of the
following transactions under the Abcam plc Share Incentive Plan ("the SIP") to
the benefit of the Executive Directors and PDMRs:
Name Partnership Shares purchased on 5 November 2009 at 935 Matching Shares awarded on 5 November 2009 at 935 pence Free Shares awarded on 9 November 2009 at 904 pence
pence per share per share per share
Jonathan Milner 160 160 331
Jim Warwick 160 160 331
Jeff Iliffe 160 160 331
Mark Bushfield 13 13 331
Jane Cooke 160 160 331
Philippe Cotrel 60 60 331
The risk of forfeiture attached to the Matching Shares will normally be removed
on the third anniversary of the award subject to continued employment and the
retention of the Partnership Shares in connection with which they were awarded.
The risk of forfeiture attached to the Free Shares will normally be removed on
the third anniversary of the award subject to continued employment.
No consideration was paid by the above grantees for the award of the Matching
Shares or Free Shares and no consideration is due on the release of the Matching
or Free Shares.
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeffrey Iliffe, Chief Financial Officer
Numis Securities + 44 (0) 20 7260 1000
Michael Meade / Nick Westlake - Nominated Adviser
James Black - Corporate Broking
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered
in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA,
Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and
trades under the ticker symbol ABC. The Company produces and distributes its own
and third-party produced antibodies to academic and commercial users throughout
the world. Product ordering is available through the Company's website
www.abcam.com, where customers are also able to access up-to-date and detailed
technical product data sheets. All the antibodies are sold under the Abcam brand
name and the Company's vision is to build the world's largest online resource of
high-quality and commercially viable antibodies. Abcam now has an online
catalogue of over 56,000 products, most of which are antibodies, from over 250
suppliers and employs 243 staff in its four operating companies.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSVKLFBKFBBFBL
back to RNS news